Jacob Petersen

Bio:

Jacob Petersen is currently the Senior Vice President, Head of Diabetes, Obesity and MASH Therapy Area in Research and Early Development. This area also includes Cell Therapies where he is responsible for the future standard of care for diabetes, obesity and MASH by providing transformative, preventive and cell therapy curative treatments together with partners. This therapy organization focuses on external partnerships, speed, differentia-tion, scalability and enterprise thinking across the value chain.

Previously, he was head of Global Nucleic Acid Therapies, developing next-generation siRNA and gene therapies. This area included the integration of the legacy Dicerna Pharma-ceuticals team which was purchased by Novo Nordisk in 2021.

Jacob’s extensive 30+ year career at Novo Nordisk has included various research leadership positions of growing size and complexity, and positions such as the Corporate Vice Presi-dent, Head of Cell Therapies R&D where he was responsible for building a new organiza-tion with full R&D value chain capabilities including manufacturing and devices. Jacob was also the Head of Global Research within metabolic diseases including diabetes, obesity, car-diovascular disease, liver disease, kidney disease, beta cells, and type 1 diabetes.

Jacob has more than 70 published papers in peered reviewed journals and has been an ad-junct professor at Copenhagen University in Biomedicine. Jacob holds several board posi-tions including Chairman of the Board of Ketotic Hypoglycemia International, board mem-ber at Novo Nordisk Pharmatec A/S and Alliance for Regenerative Medicine (ARM).

Jacob is currently located in the Boston area where he since 2023 also serves as the site head to Novo Nordisk’s US Research and Development Boston Hub.